Abstract:Introduction: Although PD-1/L1 mAb has demonstrated clinical benefits in certain cancer types, low response rate and resistance remain the main challenges for the application of these immune checkpoint inhibitors (ICIs). 4-1BB is a co-stimulator molecule expressed in T cells, which could enhance T cell proliferation and activation. Herein, the synergetic antitumor effect and underlying mechanism of 4-1BB agonist combined with PD-1/PD-L1 blockade were determined in B-cell lymphoma (BCL). Methods: Subcutaneous transplantation BCL tumor models and metastasis models were established to evaluate the therapeutic effect of PD-L1 antibody and/or 4-1BB agonist in vivo. For the mechanistic study, RNA-seq was applied to analyze the tumor microenvironment and immune-related signal pathway after combination treatment. The level of IFN-γ, perforin, and granzyme B were determined by ELISA and Real-time PCR assays, while tumor-infiltrating T cells were measured by flow cytometry and immunohistochemical analysis. CD4/CD8 specific antibodies were employed to deplete the related T cells to investigate the role CD4+ and CD8+ T cells played in combination treatment. Results: Our results showed that combining anti-PD-L1 ICI and 4-1BB agonists elicited regression of BCL and significantly extended the survival of mice compared to either monotherapy. Co-targeting PD-L1 and 4-1BB preferentially promoted intratumoral cytotoxic lymphocyte infiltration and remodeled their function. RNA-sequence analysis uncovered a series of up-regulated genes related to the activation and proliferation of cytotoxic T lymphocytes, further characterized by increased cytokines including IFN-γ, granzyme B, and perforin. Furthermore, depleting CD8+ T cells not CD4+ T cells totally abrogated the antitumor efficacy, indicating the crucial function of the CD8+ T cell subset in the combination therapy. Discussion: In summary, our findings demonstrated that 4-1BB agonistic antibody intensified the antitumor immunity of anti-PD-1/PD-L1 ICI via promoting CD8+ T cell infiltration and activation, providing a novel therapeutic strategy to BCL.

Interfering B cell receptor signaling via SHP-1/p-Lyn axis shows therapeutic potential in diffuse large B-cell lymphoma

Synergistic Lethality Effects of ABT-199 and Apatinib on DLBCL: Antitumor Efficacy and Underlying Mechanisms

Apatinib Enhances Chemosensitivity of ABT-199 in Diffuse Large B-cell Lymphoma

A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality with BTK or MDM2-P53 Inhibitor in Diffuse Large B-Cell Lymphoma.

A promising natural product in diffuse large B-cell lymphoma therapy by targeting PIM1

PD-L1 Over-Expression is Driven by B-cell Receptor Signaling in Diffuse Large B-cell Lymphoma

Sphingosine kinase 1 counteracts chemosensitivity and immune evasion in diffuse large B cell lymphoma cells via the PI3K/AKT/PD-L1 axis

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Molecular Biomarker Exploration of Rituximab plus CHOP Therapy in Real-World Diffuse Large B-Cell Lymphoma Patients

S 1 PR 1 is an Effective Target to Block STAT 3 Signaling in Activated B Cell – Like Diffuse Large B-cell Lymphoma

Irreversible Dual Inhibitory Mode: the Novel Btk Inhibitor PLS-123 Demonstrates Promising Anti-Tumor Activity in Human B-cell Lymphoma.

B-cell Receptor-Mediated NFATc1 Activation Induces IL-10/STAT3/PD-L1 Signaling in Diffuse Large B-cell Lymphoma

First-in-class inhibitor of HSP110 blocks BCR activation through SYK phosphorylation in diffuse large B-cell lymphoma

Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma

Co-Targeting of BTK and TrxR as a Therapeutic Approach to the Treatment of Lymphoma

Frequent expression of PD-L1 in BLS-type diffuse large B-cell lymphoma: implications for aggressiveness and immunotherapy

Synergistic Effect of Programmed Death-1 Inhibitor and Programmed Death-1 Ligand-1 Inhibitor Combined with Chemotherapeutic Drugs on DLBCL Cell Lines in Vitro and in Vivo.

Inhibition of the PI3K/AKT Signaling Pathway Sensitizes Diffuse Large B-cell Lymphoma Cells to Treatment with Proteasome Inhibitors Via Suppression of BAG3

Marine sponge-derived alkaloid inhibits the PI3K/AKT/mTOR signaling pathway against diffuse large B-cell lymphoma

Preclinical Efficacy and Biological Effects of the Oral Proteasome Inhibitor Ixazomib in Diffuse Large B-cell Lymphoma.

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma